India Pharma Outlook Team | Monday, 22 September 2025
Pfizer Inc. revealed that it is acquiring Metsera, Inc. for $4.9 billion in cash, further enhancing its pipeline in obesity and cardio-metabolic diseases.
The definitive agreement was approved unanimously by both companies' boards and is a strengthening of Pfizer's commitment for one of the fastest growing therapeutic areas.
“Obesity is a large and growing space with over 200 health conditions associated with it. The proposed acquisition…Pfizer into this key therapeutic area,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer.
Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation
Metsera is a clinical stage biopharma and has a broad array of oral and injectable candidates for obesity. Metsera's pipeline includes MET-097i, a weekly and monthly injectable GLP-1 receptor agonist which is in the Phase 2 trials, and MET-233i, a monthly amylin analog in a Phase 1 trial alone and in combination with MET-097i.
The company is also advancing two oral GLP-1 candidates expected to enter clinical trials soon, along with several additional preclinical programs. Initial data on MET-233i presented at the last European Association for the Study of Diabetes meeting suggest a potential best-in-class efficacy and tolerability.
“Since our founding in 2022, Metsera has worked tirelessly to reduce the physical, emotional, and economic burdens of obesity with a portfolio of next generation nutrient-stimulated hormone therapeutic candidates,” said Whit Bernard, Co-Founder and Chief Executive Officer of Metsera.
Per the terms of the agreement, Pfizer will pay Metsera $47.50 per share in cash, in addition to a contingent value right valued at up to $22.50 per share linked to clinical and regulatory milestones to be met. The transaction is expected to close in Q4 2025, pending Metsera shareholder and customary regulatory approvals. Pfizer said it would update its financial outlook at its upcoming quarterly results.
